{"id":458501,"date":"2021-03-16T08:03:18","date_gmt":"2021-03-16T12:03:18","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=458501"},"modified":"2021-03-16T08:03:18","modified_gmt":"2021-03-16T12:03:18","slug":"immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\/","title":{"rendered":"Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD\u2019s KEYTRUDA\u00ae (pembrolizumab) in 1st line head and neck squamous cell carcinoma (HNSCC)<\/li>\n<li>HNSCC is one of the more common cancers worldwide and has a high unmet medical need<\/li>\n<li>First patient is expected to be enrolled in mid-2021<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Sydney, AUSTRALIA, March  16, 2021  (GLOBE NEWSWIRE) &#8212; <\/strong>\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XLIstIttOCgvM65rs74NmGZ_hx7h14amVPBEPm2z6__iD-AWYcaBdpWHtWfAk5fUh-LBmD9FsQGA1V8hwe7Tdg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Immutep Limited<\/a> (<strong>ASX: IMM; NASDAQ: IMMP<\/strong>) (&#8220;Immutep\u201d or \u201cthe Company\u201d), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, announces a second clinical trial collaboration and supply agreement with subsidiaries of Merck &amp; Co., Inc., Kenilworth, NJ, USA (known as \u201cMSD\u201d outside the United States and Canada). Under the agreement, Immutep will conduct a new Phase IIb clinical trial in 1st line HNSCC patients, as initially described in the ASX announcement dated 28 September 2020.<\/p>\n<p align=\"justify\">The trial, called TACTI-003 (Two Active Immunotherapies), will be a 1:1 randomised, controlled clinical study in approximately 160 1<sup>st<\/sup> line HNSCC patients. It will evaluate the safety and efficacy of Immutep\u2019s lead product candidate, eftilagimod alpha (efti or IMP321), when given in combination with MSD\u2019s KEYTRUDA\u00ae (pembrolizumab), compared to pembrolizumab alone. TACTI-003 will take place in 20+ clinical sites in the United States, Australia and Europe, and the first patient is expected to be enrolled in mid-2021.<\/p>\n<p align=\"justify\">The combination of efti and KEYTRUDA is also being evaluated in Immutep\u2019s ongoing Phase II TACTI-002 study. The promising clinical results generated to date from the TACTI-002 trial have prompted the initiation of the new TACTI-003 trial. The combination brings together two immuno-oncology treatments with complementary mechanisms of action at two different positions in the cancer immunity cycle. Efti is a first-in-class antigen presenting cell activator which stimulates cancer-fighting T cells, while KEYTRUDA is an anti-PD-1 therapy which blocks the immunosuppressive PD-1 pathway.<\/p>\n<p align=\"justify\">\u201cWe are excited to be deepening our collaboration with MSD through this second agreement and the TACTI-003 clinical trial. Advancing to this later stage Phase IIb trial will allow us to explore the combination therapy in the commercially relevant 1<sup>st<\/sup> line therapy setting which has a high unmet medical need,\u201d said Immutep CEO Marc Voigt.<\/p>\n<p align=\"justify\">HNSCC is the sixth most common cancer by incidence worldwide, with 890,000 new cases and 450,000 deaths reported in 2018.<sup>1<\/sup><sup>,<\/sup><sup>2<\/sup><sup>,<\/sup><sup>3<\/sup> HNSCC is an aggressive, genetically complex, and difficult to treat cancer.<sup>4<\/sup> Furthermore, HNSCC is associated with high levels of psychological distress and compromised quality of life (QOL).<sup>5<\/sup> As such, patients with HNSCC are very much in need of improved treatment options.<\/p>\n<p align=\"justify\">\n        <strong>About Immutep<\/strong><br \/>\n        <br \/>Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer, infectious disease and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.<\/p>\n<p align=\"justify\">Immutep\u2019s current lead product candidate is eftilagimod alpha (efti or IMP321), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep\u2019s large pharmaceutical partners.<\/p>\n<p align=\"justify\">Further information can be found on the Company\u2019s website <u>www.immutep.com<\/u> or by contacting:<\/p>\n<p align=\"justify\">KEYTRUDA\u00ae is a registered trademark of Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., Kenilworth, NJ, USA.<\/p>\n<p align=\"justify\">\n        <strong>Australian Investors\/Media:<\/strong><br \/>\n        <br \/>Catherine Strong, Citadel-MAGNUS<br \/>+61 (0)406 759 268; <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HnDjduQdsRsFLYRaDZLuxMZJDLgnLERkKoK8y-JJn9SQ1cvXnXUVj-YGJlr7UHVPHMubcGnpg7a_8LTvTUdJXqn1o-w1wB16URgxtPEt7TY=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">cstrong@citadelmagnus.com<\/a><\/u><\/p>\n<p align=\"justify\">\n        <strong>U.S. Media:<\/strong><br \/>\n        <br \/>Tim McCarthy, LifeSci Advisors<br \/>+1 (212) 915.2564;\u00a0<u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gEaLjr7-agH_su648MxvfmjoZVfaiOmnB9tTrSPrXyXx7KlYHQv0vTV0SMsFZgT_qJwBKjke4OaFvzs4gCjc3d7yWplwFGIqrSyHN_c3HvI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">tim@lifesciadvisors.com<\/a><\/u><\/p>\n<hr \/>\n<p>\n        <sup>1<\/sup> Ferlay, J. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.\u00a0<em>Int. J. Cancer<\/em>\u00a0144, 1941\u20131953 (2019).<\/p>\n<p>\n        <sup>2<\/sup> Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.\u00a0<em>CA Cancer J. Clin.<\/em>\u00a068, 394\u2013424 (2018).<\/p>\n<p>\n        <sup>3<\/sup> Ferlay, J. et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer (accessed 18 September 2020). <em>IARC<\/em><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0jpa0UWGDl_jF8zfl_aL9MXjMzSAIBBOe6k5al4ETJzyH6PNO3cwY-OIEkZ9SStmJEjrh3UMoGWD8YDMcjQ1dDI9aVTM3iz11KzBLghnZQc=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/gco.iarc.fr\/today<\/a> (2018).<\/p>\n<p>\n        <sup>4<\/sup> Alsahafi, E., Begg, K., Amelio, I.\u00a0<em>et al.<\/em>\u00a0Clinical update on head and neck cancer: molecular biology and ongoing challenges.\u00a0<em>Cell Death Dis<\/em>\u00a0<strong>10,\u00a0<\/strong>540 (2019).\u00a0<\/p>\n<p>\n        <sup>5<\/sup> Johnson, D.E., Burtness, B., Leemans, C.R.\u00a0<em>et al.<\/em>\u00a0Head and neck squamous cell carcinoma.\u00a0<em>Nat Rev Dis Primers<\/em>\u00a0<strong>6,\u00a0<\/strong>92 (2020).<\/p>\n<p>\n        \n      <\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDUyMyM0MDY1NjAwIzIwMTk4MzM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/18e5eecb-cf4a-48ac-adf2-b298db7debfb\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD\u2019s KEYTRUDA\u00ae (pembrolizumab) in 1st line head and neck squamous cell carcinoma (HNSCC) HNSCC is one of the more common cancers worldwide and has a high unmet medical need First patient is expected to be enrolled in mid-2021 Sydney, AUSTRALIA, March 16, 2021 (GLOBE NEWSWIRE) &#8212; \u00a0Immutep Limited (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep\u201d or \u201cthe Company\u201d), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, announces a second clinical trial collaboration and supply agreement with subsidiaries of Merck &amp; Co., Inc., Kenilworth, NJ, USA (known as \u201cMSD\u201d outside the United States and Canada). Under the agreement, Immutep will conduct a new Phase &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-458501","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD\u2019s KEYTRUDA\u00ae (pembrolizumab) in 1st line head and neck squamous cell carcinoma (HNSCC) HNSCC is one of the more common cancers worldwide and has a high unmet medical need First patient is expected to be enrolled in mid-2021 Sydney, AUSTRALIA, March 16, 2021 (GLOBE NEWSWIRE) &#8212; \u00a0Immutep Limited (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep\u201d or \u201cthe Company\u201d), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, announces a second clinical trial collaboration and supply agreement with subsidiaries of Merck &amp; Co., Inc., Kenilworth, NJ, USA (known as \u201cMSD\u201d outside the United States and Canada). Under the agreement, Immutep will conduct a new Phase &hellip; Continue reading &quot;Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-16T12:03:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDUyMyM0MDY1NjAwIzIwMTk4MzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer\",\"datePublished\":\"2021-03-16T12:03:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\\\/\"},\"wordCount\":730,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDUyMyM0MDY1NjAwIzIwMTk4MzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\\\/\",\"name\":\"Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDUyMyM0MDY1NjAwIzIwMTk4MzM=\",\"datePublished\":\"2021-03-16T12:03:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDUyMyM0MDY1NjAwIzIwMTk4MzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDUyMyM0MDY1NjAwIzIwMTk4MzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer - Market Newsdesk","og_description":"New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD\u2019s KEYTRUDA\u00ae (pembrolizumab) in 1st line head and neck squamous cell carcinoma (HNSCC) HNSCC is one of the more common cancers worldwide and has a high unmet medical need First patient is expected to be enrolled in mid-2021 Sydney, AUSTRALIA, March 16, 2021 (GLOBE NEWSWIRE) &#8212; \u00a0Immutep Limited (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep\u201d or \u201cthe Company\u201d), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, announces a second clinical trial collaboration and supply agreement with subsidiaries of Merck &amp; Co., Inc., Kenilworth, NJ, USA (known as \u201cMSD\u201d outside the United States and Canada). Under the agreement, Immutep will conduct a new Phase &hellip; Continue reading \"Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-16T12:03:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDUyMyM0MDY1NjAwIzIwMTk4MzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer","datePublished":"2021-03-16T12:03:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\/"},"wordCount":730,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDUyMyM0MDY1NjAwIzIwMTk4MzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\/","name":"Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDUyMyM0MDY1NjAwIzIwMTk4MzM=","datePublished":"2021-03-16T12:03:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDUyMyM0MDY1NjAwIzIwMTk4MzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDUyMyM0MDY1NjAwIzIwMTk4MzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head-and-neck-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/458501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=458501"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/458501\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=458501"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=458501"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=458501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}